Investor Presentation - First Six Months of 2021

18 Investor presentation First six months of 2021 Strategic aspirations 2025 Purpose and sustainability لا Commercial execution • • Being respected for adding value to society • Progress towards zero environmental impact Ensure distinct core capabilities and evolve culture . • Strengthen Diabetes leadership - aim at global value market share of more than 1/3 Strengthen Obesity leadership and double current sales¹ • Secure a sustained growth outlook for Biopharm Financials therapeutic focus Innovation and O|||||| • • • • • Further raise the innovation-bar for diabetes treatment Develop a leading portfolio of superior treatment solutions for obesity Strengthen and progress the Biopharm pipeline Establish presence in Other serious chronic diseases focusing on CVD, NASH and CKD Deliver solid sales and operating profit growth • Deliver 6-10% sales growth in IO . Transform 70% of sales in the US² Drive operational efficiencies across the value chain to enable investments in future growth assets Deliver free cash flow to enable attractive capital allocation to shareholders 1 Based on reported sales in 2019, 2 From 2015 to 2022, 70% of sales to come from products launched from 2015. IO: International Operations; CVD: Cardiovascular disease; NASH: Non-alcoholic steatohepatitis; CKD: Chronic kidney disease. Novo NordiskⓇ

View entire presentation